ESMO Congress 2024 Preview for Community Oncologists: The Show and After Show
Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.
As another opportunity to bridge the gap between community and academic oncologists, the European Society of Medical Oncology (ESMO) Congress 2024 will hopefully foster exchange and debate of translational cancer science and practice-changing revelations to improve treatment options for patients with cancer.
In the next episode of The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of this year’s anticipated presentations to come out of the Presidential Symposiums, as well as topics that community oncology providers hope to enhance the field even further. Some key highlights include:
Genitourinary Cancer
- EORTC-GUCG 1333/PEACE-3 trial: Silke Gillessen, MD, Department of Medical Oncology of the Università della Svizzera Italiana and Oncology Institute of Southern Switzerland, will discuss first results from the phase 3 EORTC-GUCG 1333/PEACE-3 trial comparing enzalutamide (Xtandi) vs a combination of Radium-223 and enzalutamide for asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer.
Gynecologic Malignancies
- ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945) study: Domenica Lorusso, MD, PhD, director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and professor of obstetrics and gynaecology, Humanitas University, Rozzano, will share overall survival data from the randomized, double-blind, phase 3 trial evaluating for pembrolizumab (Keytruda) plus chemoradiotherapy in high-risk locally advanced cervical cancer.
The co-hosts touch on even more presentations coming out of ESMO Congress 2024, including data from the genitourinary space, overall survival results in triple-negative breast cancer, and emerging technologies as the use of AI grows in popularity.
ESMO Congress 2024 isn't just about data, as the duo also offers food recommendations, tourist attractions and fun activities to partake in, as well as interesting facts about Barcelona.
This is just a taste of the wealth of information and inspiration waiting at ESMO Congress 2024. Check back for future meeting previews with The Show and After Show.
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
October 3rd 2024Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.
Read More
Single CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma
October 2nd 2024A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
Read More
